Who Owns Fate Therapeutics Inc (FATE)? 13F Institutional Holders (Q2 2026)

FATE ranks #3587 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

156 institutions disclose a position in FATE, but none treat it as a major bet — even Redmile Group, LLC, its most concentrated holder, allocates just 2.3% of its own portfolio to it.

Redmile Group, LLC has added to its FATE position for two straight quarters, increasing it by $22.1M to reach $34.8M today.

Dimensional Fund Advisors LP has trimmed its FATE position for two straight quarters, cutting it by $600.9K while still holding $949.1K.

FATE is down 4.3% today, but institutions show net buying of $7.3M this quarter — a divergence between today's price move and the underlying institutional flow.

FATE reported a net loss of $126.0M over the trailing twelve months.

• Not yet profitable — net loss of $126.0M over the trailing twelve months
• Revenue declined 23.4% year over year
• Net income improved year over year, from -$171.5M to -$126.0M
• Operating cash flow was negative, using $106.1M in cash
• Current ratio of 5.79x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.54x equity — within a conventional range